The transaction was non-discretionary and performed to satisfy statutory tax withholding obligations following the vesting of restricted stock units. Post-transaction, the insider maintains a direct ...
The Number $1.5 billion. That is what Tempus AI (NASDAQ:TEM) agreed to pay for Personalis (NASDAQ:PSNL) in a definitive merger announced July 20, 2026, a deal structured as a 100% stock transaction ...
This routine divestment occurred as the stock reflected a -27% return over the 12 months ending August 14, before a major stock surge. Chicago-based Tempus AI operates a healthcare technology platform ...
Hosted on MSN
Why Tempus AI skyrocketed this weekTempus AI stock surged this week after Merck and Moderna published encouraging trial results for a cancer treatment. A company that Tempus AI is acquiring provided technologies that aided the ...
Here are Cathie Wood’s latest moves.
Moderna and Merck's personalized mRNA cancer vaccine mRNA-4157 achieved a breakthrough in Phase 3 trials, triggering a sharp ...
ARK sees a path toward custom cancer treatments for every patient, though current costs of $200,000-$300,000 remain a major ...
The latest international Christy Santhosh news and views from Reuters - one of the world's largest news agencies ...
The Moderna result strengthens the strategic connection behind the Personalis deal, but it does not validate the entire ...
Moderna's Phase 3 mRNA cancer win sent TEM surging 24% and MRNA doubling over the past year, confirming Tempus's $1.5 billion Personalis bet. PSNL clinical diagnostic revenue surged 442% year over ...
Tempus has been trading back and forth on fears of AI replacing the precision medicine company to provide a tailwind to drug discovery and the use of foundational models to boost data licensing. The ...
Tempus AI (TEM) stock rose 2% after Piper Sandler upgraded it to Overweight with a $76 target, citing Personalis deal and FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results